Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) announced its quarterly earnings results on Wednesday. Vanda Pharmaceuticals Stock PerformanceShares of VNDA opened at $5.11 on Friday. Vanda Pharmaceuticals has a 12 month low of $4.14 and a 12 month high of $9.94. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Friday, July 17th. Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.Read MoreReceive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.